Comprehensive Stock Comparison
Compare Immunome, Inc. (IMNM) vs Recursion Pharmaceuticals, Inc. (RXRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | RXRX | 26.9% revenue growth vs IMNM's -35.5% |
| Quality / Margins | RXRX | -8.6% net margin vs IMNM's -23.0% |
| Stability / Safety | IMNM | Beta 1.42 vs RXRX's 2.38, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | IMNM | +132.6% vs RXRX's -51.1% |
| Efficiency (ROA) | RXRX | -43.7% ROA vs IMNM's -74.4%, ROIC -95.8% vs -7.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Immunome is a biopharmaceutical company that discovers and develops antibody therapeutics for cancer and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — as it advances its pipeline of antibody candidates. The company's key advantage lies in its proprietary discovery platform that identifies human antibodies from patient immune responses, potentially yielding more effective and safer therapeutic candidates.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses an industrialized, technology-driven platform to discover and develop new drugs. It generates revenue primarily through research collaborations and partnerships with pharmaceutical companies — like its major deal with Bayer — while advancing its own pipeline of drug candidates. Its key competitive advantage is its proprietary platform that combines automation, artificial intelligence, and massive biological datasets to systematically decode biology and accelerate drug discovery at scale.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
RXRX leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). IMNM leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
RXRX is the larger business by revenue, generating $75M annually — 7.7x IMNM's $10M. RXRX is the more profitable business, keeping -8.6% of every revenue dollar as net income compared to IMNM's -23.0%. On growth, RXRX holds the edge at +6.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $10M | $75M |
| EBITDAEarnings before interest/tax | -$232M | -$564M |
| Net IncomeAfter-tax profit | -$223M | -$645M |
| Free Cash FlowCash after capex | -$192M | -$378M |
| Gross MarginGross profit ÷ Revenue | -4.2% | -32.1% |
| Operating MarginEBIT ÷ Revenue | -24.2% | -8.7% |
| Net MarginNet income ÷ Revenue | -23.0% | -8.6% |
| FCF MarginFCF ÷ Revenue | -19.8% | -5.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +6.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +16.7% | +60.4% |
Valuation Metrics
| Metric | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|
| Market CapShares × price | $2.0B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -4.37x | -2.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 221.74x | 25.96x |
| Price / BookPrice ÷ Book value/share | 7.08x | 1.45x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
RXRX delivers a -57.0% return on equity — every $100 of shareholder capital generates $-57 in annual profit, vs $-84 for IMNM. IMNM carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to RXRX's 0.07x. On the Piotroski fundamental quality scale (0–9), RXRX scores 4/9 vs IMNM's 1/9, reflecting mixed financial health.
| Metric | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -84.4% | -57.0% |
| ROA (TTM)Return on assets | -74.4% | -43.7% |
| ROICReturn on invested capital | -7.0% | -95.8% |
| ROCEReturn on capital employed | -195.6% | -50.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.07x |
| Net DebtTotal debt minus cash | -$139M | -$665M |
| Cash & Equiv.Liquid assets | $143M | $743M |
| Total DebtShort + long-term debt | $5M | $78M |
| Interest CoverageEBIT ÷ Interest expense | — | -491.16x |
Total Returns (with DRIP)
A $10,000 investment in IMNM five years ago would be worth $5,472 today (with dividends reinvested), compared to $2,039 for RXRX. Over the past 12 months, IMNM leads with a +132.6% total return vs RXRX's -51.1%. The 3-year compound annual growth rate (CAGR) favors IMNM at 68.5% vs RXRX's -23.4% — a key indicator of consistent wealth creation.
| Metric | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +5.0% | -12.6% |
| 1-Year ReturnPast 12 months | +132.6% | -51.1% |
| 3-Year ReturnCumulative with dividends | +378.3% | -55.0% |
| 5-Year ReturnCumulative with dividends | -45.3% | -79.6% |
| 10-Year ReturnCumulative with dividends | +62.5% | -79.6% |
| CAGR (3Y)Annualised 3-year return | +68.5% | -23.4% |
Risk & Volatility
IMNM is the less volatile stock with a 1.42 beta — it tends to amplify market swings less than RXRX's 2.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMNM currently trades 79.1% from its 52-week high vs RXRX's 46.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.42x | 2.38x |
| 52-Week HighHighest price in past year | $27.65 | $7.89 |
| 52-Week LowLowest price in past year | $5.15 | $2.98 |
| % of 52W HighCurrent price vs 52-week peak | +79.1% | +46.5% |
| RSI (14)Momentum oscillator 0–100 | 42.9 | 46.7 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 18.2M |
Analyst Outlook
Wall Street rates IMNM as "Buy" and RXRX as "Hold". Consensus price targets imply 199.7% upside for RXRX (target: $11) vs 61.4% for IMNM (target: $35).
| Metric | IMNMImmunome, Inc. | RXRXRecursion Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $35.29 | $11.00 |
| # AnalystsCovering analysts | 9 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | May 21 | Feb 26 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | 100 | 104.31 | +4.3% |
| Recursion Pharmaceu… (RXRX) | 183.44 | 23.22 | -87.3% |
Immunome, Inc. (IMNM) returned -45% over 5 years vs Recursion Pharmaceu… (RXRX)'s -80%.
Chart 2Revenue Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | $0.00 | $9M | — |
| Recursion Pharmaceu… (RXRX) | $2M | $75M | +4264.8% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2019 | 2025 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | -7.6% | -32.4% | -325.3% |
| Recursion Pharmaceu… (RXRX) | -36.5% | -8.6% | +76.4% |
Recursion Pharmaceuticals, Inc.'s net margin went from -37% (2019) to -9% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Immunome, Inc. (IMNM) | -7.18 | -5 | +30.4% |
| Recursion Pharmaceu… (RXRX) | -0.37 | -1.44 | -285.9% |
Chart 5Free Cash Flow — 5 Years
Immunome, Inc. generated $-164M FCF in 2024 (-798% vs 2021). Recursion Pharmaceuticals, Inc. generated $-378M FCF in 2025 (-91% vs 2021).
IMNM vs RXRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is IMNM or RXRX a better buy right now?
Analysts rate Immunome, Inc. (IMNM) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMNM or RXRX?
Over the past 5 years, Immunome, Inc. (IMNM) delivered a total return of -45.3%, compared to -79.6% for Recursion Pharmaceuticals, Inc. (RXRX). A $10,000 investment in IMNM five years ago would be worth approximately $5K today (assuming dividends reinvested). Over 10 years, the gap is even starker: IMNM returned +62.5% versus RXRX's -79.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMNM or RXRX?
By beta (market sensitivity over 5 years), Immunome, Inc. (IMNM) is the lower-risk stock at 1.42β versus Recursion Pharmaceuticals, Inc.'s 2.38β — meaning RXRX is approximately 68% more volatile than IMNM relative to the S&P 500. On balance sheet safety, Immunome, Inc. (IMNM) carries a lower debt/equity ratio of 3% versus 7% for Recursion Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — IMNM or RXRX?
Recursion Pharmaceuticals, Inc. (RXRX) is the more profitable company, earning -863.4% net margin versus -32.4% for Immunome, Inc. — meaning it keeps -863.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RXRX leads at -867.9% versus -33.8% for IMNM. At the gross margin level — before operating expenses — IMNM leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — IMNM or RXRX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is IMNM or RXRX better for a retirement portfolio?
For long-horizon retirement investors, Immunome, Inc. (IMNM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2.38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMNM: +62.5%, RXRX: -79.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between IMNM and RXRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.